Daniel Hubschmann
Overview
Explore the profile of Daniel Hubschmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hamacher R, Pabst K, Cheung P, Heilig C, Hullein J, Liffers S, et al.
J Nucl Med
. 2024 Jan;
65(2):252-257.
PMID: 38176718
Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its...
12.
Schopf J, Uhrig S, Heilig C, Lee K, Walther T, Carazzato A, et al.
Nat Commun
. 2024 Jan;
15(1):51.
PMID: 38168093
Linking clinical multi-omics with mechanistic studies may improve the understanding of rare cancers. We leverage two precision oncology programs to investigate rhabdomyosarcoma with FUS/EWSR1-TFCP2 fusions, an orphan malignancy without effective...
13.
Gatz S, Harttrampf A, Brard C, Bautista F, Andre N, Abbou S, et al.
Clin Cancer Res
. 2023 Dec;
30(4):741-753.
PMID: 38051741
Purpose: AcSé-ESMART Arm C aimed to define the recommended dose and activity of the WEE1 inhibitor adavosertib in combination with carboplatin in children and young adults with molecularly enriched recurrent/refractory...
14.
Deininger L, Jung-Klawitter S, Mikut R, Richter P, Fischer M, Karimian-Jazi K, et al.
Sci Rep
. 2023 Dec;
13(1):21231.
PMID: 38040865
Cerebral organoids recapitulate the structure and function of the developing human brain in vitro, offering a large potential for personalized therapeutic strategies. The enormous growth of this research area over...
15.
Mock A, Teleanu M, Kreutzfeldt S, Heilig C, Hullein J, Mohrmann L, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):109.
PMID: 37884744
Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional...
16.
Liebers N, Bruch P, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, et al.
Nat Cancer
. 2023 Oct;
4(12):1648-1659.
PMID: 37783805
Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted...
17.
Wurm A, Brilloff S, Kolovich S, Schafer S, Rahimian E, Kufrin V, et al.
Cell Rep Med
. 2023 Sep;
4(10):101200.
PMID: 37734378
Targeted therapies are effective in treating cancer, but success depends on identifying cancer vulnerabilities. In our study, we utilize small RNA sequencing to examine the impact of pathway activation on...
18.
Lauinger M, Christen D, Klar R, Roubaty C, Heilig C, Stumpe M, et al.
Sci Adv
. 2023 Sep;
9(35):eade7486.
PMID: 37656784
In-frame exon 12 deletions are increasingly identified in various tumor types. The resultant BRAF oncoproteins usually lack five amino acids in the β3-αC helix linker and sometimes contain de novo...
19.
Yildiz Y, Hubschmann O, Karaosmanoglu A, Manti F, Karaca M, Schwartz I, et al.
J Inherit Metab Dis
. 2023 Jul;
47(3):431-446.
PMID: 37452721
Elevated serum prolactin concentrations occur in inherited disorders of biogenic amine metabolism because dopamine deficiency leads to insufficient inhibition of prolactin secretion. This work from the International Working Group on...
20.
Remde H, Schmidt-Pennington L, Reuter M, Landwehr L, Jensen M, Lahner H, et al.
Eur J Endocrinol
. 2023 Jun;
188(6):485-493.
PMID: 37260092
Objective: Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a...